These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 20345506)

  • 61. Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR.
    Michelson P; Watkins B; Webber SA; Wadowsky R; Michaels MG
    Pediatr Transplant; 2008 Jun; 12(4):464-8. PubMed ID: 18466434
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation: a case report, meta-analysis, and systematic review.
    Su YY; Yu YF; Yan ZY; Zhao YJ; Lou JW; Xue F; Xu M; Feng Q; Ji XB; Dong XY; Wang W; Liu CF; Peng J; Liu XG
    Diagn Pathol; 2024 Sep; 19(1):122. PubMed ID: 39244586
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
    G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
    Ru Y; Chen J; Wu D
    Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
    [TBL] [Abstract][Full Text] [Related]  

  • 65. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
    Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
    Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.
    Chen DB; Song QJ; Chen YX; Chen YH; Shen DH
    Int J Hematol; 2013 Jan; 97(1):117-24. PubMed ID: 23255160
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fatal non-transplant-related epstein-barr virus-associated atypical lymphoid proliferations in infants and children: a clinicopathologic study.
    Salama ME; Parham DM; Perkins SL; Bahler DW; Ellison DA
    Pediatr Dev Pathol; 2008; 11(6):443-9. PubMed ID: 18473605
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Han TT; Xu LP; Liu DH; Liu KY; Zhang XH; Chen H; Chen YH; Han W; Wang FR; Wang Y; Wang JZ; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):651-4. PubMed ID: 23978013
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases.
    Kojima M; Morita Y; Nakamura N; Shimizu K; Murayama K; Nakamura S
    Pathol Res Pract; 2008; 204(4):267-72. PubMed ID: 18187262
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunotherapy for Epstein-Barr virus-associated malignancies.
    Long HM; Parsonage G; Fox CP; Lee SP
    Drug News Perspect; 2010 May; 23(4):221-8. PubMed ID: 20520851
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Epstein-Barr virus (EBV) gene expression in interstitial pneumonitis in Brazilian human immunodeficiency virus-1-infected children: is EBV associated or not?
    Toro AA; Altemani AM; da Silva MT; Morcillo AM; Vilela MM
    Pediatr Dev Pathol; 2010; 13(3):184-91. PubMed ID: 19968485
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Utility of quantitative EBV DNA measurements in cerebrospinal fluid for diagnosis and monitoring of treatment of central nervous system EBV-associated post-transplant lymphoproliferative disorder after allogenic hematopoietic stem cell transplantation.
    Bocian J; Januszkiewicz-Lewandowska D
    Ann Transplant; 2014 May; 19():253-6. PubMed ID: 24866354
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
    Naik S; Riches M; Hari P; Kim S; Chen M; Bachier C; Shaughnessy P; Hill J; Ljungman P; Battiwalla M; Chhabra S; Daly A; Storek J; Ustun C; Diaz MA; Cerny J; Beitinjaneh A; Yared J; Brown V; Page K; Dahi PB; Ganguly S; Seo S; Chao N; Freytes CO; Saad A; Savani BN; Woo Ahn K; Boeckh M; Heslop HE; Lazarus HM; Auletta JJ; Kamble RT
    Transpl Infect Dis; 2019 Oct; 21(5):e13145. PubMed ID: 31301099
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
    Luo XY; Mo XD; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Zhao XY; Huang XJ
    Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
    [TBL] [Abstract][Full Text] [Related]  

  • 77. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma.
    Isobe Y; Aritaka N; Setoguchi Y; Ito Y; Kimura H; Hamano Y; Sugimoto K; Komatsu N
    J Clin Pathol; 2012 Mar; 65(3):278-82. PubMed ID: 22247563
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.
    Chiereghin A; Bertuzzi C; Piccirilli G; Gabrielli L; Squarzoni D; Turello G; Ferioli M; Sessa M; Bonifazi F; Zanoni L; Sabattini E; Lazzarotto T
    Transpl Immunol; 2016 Feb; 34():60-4. PubMed ID: 26687013
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Role of Epstein-Barr virus status and immunophenotypic studies in the evaluation of exfoliative cytology specimens from patients with post-transplant lymphoproliferative disorders.
    Gibson SE; Picarsic J; Swerdlow SH; Pantanowitz L
    Cancer Cytopathol; 2016 Jun; 124(6):425-35. PubMed ID: 26992116
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
    Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
    Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.